Categories Consumer, Earnings

Kellogg (NYSE: K): Q4 2019 Earnings Snapshot

— Kellogg (NYSE: K) reported its fourth-quarter 2019 adjusted earnings of $0.91 per share versus $0.85 per share expected.

— Net sales decreased by 2.8% to $3.22 billion versus $3.18 billion expected. The absence of results from divested businesses lowered net sales by nearly 6%.

Kellogg (K) Q4 2019 earnings results

— In North America, frozen foods sales and consumption growth continued in the fourth quarter, led by its leading brand of frozen plant-based meat alternatives, MorningStar Farms, which again grew consumption at a double-digit rate while gaining share.

— In North America, cereal sales and consumption declines moderated as its growth and share gains accelerated in the taste-fun segment, led by key brands Frosted Flakes, Froot Loops, Corn Pops, and Krave behind the increased commercial activity.

— In Europe, sales growth was benefited by snacks and particularly the sustained consumption growth momentum for Pringles. Cereal sales continued to stabilize, led by overall consumption growth in the region.

— In Latin America, softened macroeconomic conditions in Puerto Rico, Argentina, and Brazil, along with distributor transitions in Central America hurt the sales. The ramp-up of new production facilities in Brazil for Pringles and cereal created incremental costs in the quarter.

— In Asia Pacific, the Middle East and Africa, sales growth was benefited by the expansion of Pringles and noodles, continued growth by Multipro in West Africa, cereal and snack growth in Asia, and Pringles and cereal consumption growth in Australia.

— Looking ahead into 2020, the company expects organic net sales growth of 1-2%. Adjusted EPS, on a currency-neutral basis, is predicted to decline by 3-4% due to the absence of results from divested businesses.

We’re on Flipboard! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top